KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods: 2012-2021

Historic Finished Goods for TherapeuticsMD (TXMD) over the last 10 years, with Dec 2021 value amounting to $2.9 million.

  • TherapeuticsMD's Finished Goods rose 42.36% to $4.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $4.5 million, marking a year-over-year increase of 42.36%. This contributed to the annual value of $2.9 million for FY2021, which is 12.30% down from last year.
  • Per TherapeuticsMD's latest filing, its Finished Goods stood at $2.9 million for FY2021, which was down 12.30% from $3.4 million recorded in FY2020.
  • TherapeuticsMD's Finished Goods' 5-year high stood at $5.0 million during FY2019, with a 5-year trough of $1.5 million in FY2017.
  • In the last 3 years, TherapeuticsMD's Finished Goods had a median value of $3.4 million in 2020 and averaged $3.8 million.
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 95.84% in 2018, then plummeted by 32.69% in 2020.
  • Yearly analysis of 5 years shows TherapeuticsMD's Finished Goods stood at $1.5 million in 2017, then soared by 95.84% to $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then slumped by 32.69% to $3.4 million in 2020, then dropped by 12.30% to $2.9 million in 2021.